English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Aspirin is the most frequently used antiplatelet therapy after percutaneous coronary intervention(PCI). Yet, the optimal daily dose of aspirin is unanswered.Objectives: We aimed to compare the effect of high-dose versus low-dose aspirin in a randomized trial ofpatients with ST-segment elevation myocardial infarction (STEMI) undergoing PCI.Patients and Methods: In a double-blind randomized trial, 175 patients with STEMI were randomly assigned tohigh-dose or low-dose aspirin. The primary efficacy outcome was major adverse cardiovascular events (MACE)as a composite endpoint of death, myocardial infarction, stroke and revascularization procedures. The primarysafety endpoint was major bleeding.Results: Totally 90 and 85 patients were assigned to high-dose and low-dose aspirin, respectively. The incidencerate of MACE was 13.1 and 10.1 per 100 person year in high-dose and low dose aspirin, respectively. There wasno significant difference between high-dose and low-dose aspirin in terms of efficacy (Adjusted hazard ratio:0.85, 95% CI=0.29-2.45) and safety outcome (Adjusted hazard ratio: 1.65, 95% CI=0.41-6.69).Conclusion: Efficacy and safety outcomes were not significantly different between high-dose and low-doseaspirin.

immunopathologia persa

Safety and efficacy of high-dose versus low-dose aspirin in individuals with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized clinical trial